Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ATAI Life Sciences NV
ATAI
Healthcare
Biotechnology
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B...
receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ATAI)
New Post
View:
Posts & Comments
Threaded Posts
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 13, 2024 9:32pm
atai Life Sciences Reports Second Quarter 2024 Financial Res
JUST IN: $ATAI atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates@ Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 09, 2024 7:00pm
Missouri to Use $10M from Opioid Funds to Study Psilocybin
News; $ATAI Missouri to Use $10M from Opioid Funds to Study PsilocybinLegislators in the House of Representatives in the state of Missouri have awarded preliminary approval to a budget measure that
...more
Access North American AND Australian listed and Pre-IPO opportunities – here!
posted Dec 27, 2024 9:00am by
Stockhouse Publishing Ltd.
-
|
For the first time on Stockhouse, Canadian investors can access ASX-listed opportunities through our partnership with HotCopper in Australia, opening doors to high-potential investments at the click of a button. Learn more here… ...read more
(0)
•••
StockJunkie4994
X
View Profile
View Bullboard History
Post by
StockJunkie4994
on May 08, 2023 11:49am
Top 5 Shroom Stocks
https://thedalesreport.com/psychedelics/tdrs-top-5-psychedelic-developments-for-the-week-of-may-1/
(0)
•••
Karylle
X
View Profile
View Bullboard History
Post by
Karylle
on Apr 13, 2023 4:10am
Kevin Harrington Discusses FSD Pharma
I believe this new product will aid society in reducing the
...more
(0)
•••
Karylle
X
View Profile
View Bullboard History
Post by
Karylle
on Jul 15, 2022 9:45pm
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent
(0)
•••
Karylle
X
View Profile
View Bullboard History
Post by
Karylle
on Jun 03, 2022 5:29am
FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance
FSD Pharma ready to proceed with Phase 2 clinical trial of
...more
(0)
•••
Karylle
X
View Profile
View Bullboard History
Post by
Karylle
on Jun 02, 2022 12:39am
FSD Pharma Files Investigational New Drug Application “IND”
(0)
•••
Karylle
X
View Profile
View Bullboard History
Post by
Karylle
on May 11, 2022 1:53am
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets
(0)
•••
Karylle
X
View Profile
View Bullboard History
Post by
Karylle
on May 03, 2022 1:41am
Lucid-MS for Multiple Sclerosis Treatment
(0)
•••
Karylle
X
View Profile
View Bullboard History
Post by
Karylle
on Apr 25, 2022 2:33am
"Julia Levy Award" Recipient David Allan and Dr. John McGraw
(0)
•••
Karylle
X
View Profile
View Bullboard History
Post by
Karylle
on Apr 18, 2022 2:40am
FSD Pharma Inc: Lucid MS Video
FSD Pharma is delighted to announce pre-clinical findings
...more
(0)
•••
Karylle
X
View Profile
View Bullboard History
Post by
Karylle
on Apr 09, 2022 12:55pm
FSD: Cancellation of Certain Shares Issued to Former CEO
FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A)
...more
(0)
•••
Karylle
X
View Profile
View Bullboard History
Post by
Karylle
on Apr 07, 2022 1:05pm
FSD Pharma Issues Corporate Updates
FSD Pharma Issues Corporate Updates TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to
...more
(433)
•••
AwareInvestor
X
View Profile
View Bullboard History
Post by
AwareInvestor
on Jun 18, 2021 7:54am
Atai Life Sciences Increases IPO To $225 Million
Atai Life Sciences late last night announced the pricing of its upsized initial public offering. The clinical-stage biotech firm now expects its IPO to raise gross proceeds of roughly $225.0 million
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Why Dozens of Pro Athletes are Paying Attention to this Product
Debt-Free Cannabis Company Set for Next Stage of Growth
Growth Rocket 2025 – Why dynaCERT is in the Spotlight
A potential breakthrough in spinal cord and optic nerve injury treatment
Learn How this Company is Disrupting Point-of-Care Testing